Member Info for Saxondale

Is it land ahoy !??
Please let it be this time !

That share sale has been on the Faron website for all to see . I saw it . She's a young person , who needs to live . She's not Timo . Its a non event .
Lets not all fall into the same trap as many LSE BB's of dealing with pointless arguments .

I like to think the Faron board is a united front . Whats the point of being an investor if you are not 100% behind the company . That would just make you a gambler or a time waster .

The UK side of investors , in my opinion , have made their investment , and hold until further notice . Very little trading . We have had week upon week of virtually zero trading . Now however , we are moving into the Goldilocks zone . The next few months may well get choppy , as bigger fish start to take positions , so expect shenanigans and timewasters .
That's the stockmarket . Short term , it gives some opportunities , and others a headache .

Either way - those that are seriously invested here are looking forward to a rosy future .

DonaldT , I understand exactly what you a saying , a bird in the hand is worth two in the bush .

Every month this drags on , there are risks of running out of money , some competitor getting ahead of us in some way or another , or us hitting a brick wall by some new discovery that doesn't help us or worse still invalidates our gains ( see Traumakine and steroids ).

From one point of view - we were promised SSV , a deal / partner . Now the strategy changes , be patient etc...

So the risk is still there , as it always was . It's our choices how we interpret it .

Statistically , this is a risky share . But is is more or less risky than it was 2 years ago ? I'd say less .

I haven't got all my eggs here , so if if circumstances change and we end up losing , I will survive to fight on .

But I really only see positives in the recent moves to postpone any deals in favour of waiting for more data .

The game has changed - so should the goalposts .

The Merck prospect with Keytruda for example - means we need to wait longer to see results . But what a massive jackpot that could be .

I'd love some smaller deal to be struck to cement Bex as a going concern , get some approval and build from there via a steady stream of income .

Lets just see what comes . A few weeks and will surely know if risk is further reduced .

Until then , if losing 60-80% here will be a big problem short term , investors should reconsider .

I know the risks . Maybe I always sound very positive , but I do understand I could lose it all .

I think I've found the listing for our Late Breaking Abstract on the ESMO 2021 Programme
Friday 17th 1.30 - 2.50pm Channel 4
LBA38 - Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

Presented by Dr Petri Bono - hes the Principle Investigator of the matins trial on Bex .
Its followed by a discussion and then Live Q&A .

So the Proactive Forum Evening is on the evening before , on the 16th .

I wonder if the info will be released in time for him to discuss it .

Very sad news . Commiserations .
Most invested here are well researched as how improved your chances would be if treated with SNG001 on severe onset of symptoms . Personally , I'm keeping my fingers crossed that by Winter , SNG001 will be available in the UK on the NHS , and perhaps by early 2022 available for home use . Like the testing , I'm sure they will want to roll it out by professionals first just to make sure everyone understands its characteristics .
As I'm in my early 50s in good health , I'd like to think I'd put up a good fight , but Covid does seem to be a bit more unpredictable than we'd like to think .
I know that once its available , I'll be a lot more relaxed knowing that if I ever got in that situation , a real proper bit of therapy will have been deployed ready to help me , whether it be at home or hospital .

Faron are now trialing their I/V version , and putting it head to head against dexamethasone too , to see what gives best results as the initial treatment . The science points towards Interferon beta being the better first treatment , and steroids really should only be a back up if Interferon fails .
I'm invested heavily in both , although if I had the choice , I think I'd rather take a nebuliser if I was still able to , and keep myself as far away from a hospital as possible .

Heikkinen - that was fantastic - thanks indeed !

A great insight for us -

What a great interview
I think we should all be very excited about whats coming .
Everything he says makes sense , even leaving the patent approval to the last minute to gain extra years of exclusivity . Imagine is they'd done it in 2011 - you'd have lost 10 years !
We forget about these things - everything has been planned for maximum shareholder benefit
He singing from the same hymnbook as me . Starting to think he's stealing some of my explanations .
Ok he used Bakery instead of Chickens but I wouldn't be suprised at the next interview he says ' It's Happening ' lol

I see your point Donald - about risk .
Yes a partner would give the shareholders a boost to the SP so those wanting to take profit could , and give the company plenty of cash to continue with , but would it have prevented the total SP collapse after the failed trial such as Interest.
The SP would have tanked with a partner then too .

Either way , as it was , it led to some bottom of the barrel placings just to keep the wheels turning .
But I feel Faron are in a different space now .

The risk has been reduced drastically by having 2 clinical therapies now instead of one . And Bex has 9 cohorts that have shown positive data , with 4 that would already qualify for P3 study . Then the same amount of combination studies to come too next year .
Then the ARDS drug that post hoc analysis proved it should be a success , also having extra arms of study to come . And the Covid demand that is crying out for something is just immense .

Then the risk reduction from DOfD funding , EIC funding , Business Finland soft loans . Share holders didn't have to shoulder any dilution there .

So we have plenty of 'soft' partner relationships already ongoing , as well as the risk being reduced by a robust set of P2 data , manufacturing agreements in place , and strong and increasing IP protection globally .

The we have Heamatokine , which won't be far away from clinical study .

Every share is a risk , but I think we are a lot safer than we were .

Yes most drugs do fail trials . No eggs hatch . We've laid a nestfull and some have hatched now , so we can call that a success .

I don't know where I'm going with this egg thing now , what I think I'm trying to say is that a chicken is worth more than an egg lol .

I think that the fact we haven't signed deal yet is frankly fantastic news .
Faron would have had their chance all the way back from 2018 with Clevegen to strike some kind of deal - but at what price ? Would they have got proper fair value for it ?
From what we know now , certainly not .
Like Santhi says , the longer we can go , and the more postive data comes in , the bigger the price tag .

Even Markku thinks that the biggest cash cow potentials are relating to the trials that haven't even recruited a patient yet - the combination trials with PDL-1 Lung cancer for example . He has multiple slides showing the potential upside for both Merck and Faron .
No need for a quick sale - the golden goose is laying eggs left right and centre . Why sell the goose now ?

We are moving into the high stakes arena now .
They can't take away the data - it's in the bank .

Now that Hibiscus is running - and Delta is raging in the States , there's a chance those 70 patients will get doses pretty quick , and we may get an interim in Q4 this year .

You have ESMO in about 3 weeks , something fairly robust is going to be presented there , for sure .
But I think we will be getting a raft of updates on all sorts through Q4 that should keep investors interested .

Main market or Nasdaq will certainly be on their mind too .

But it's a long term plan - funding ? I dismissed Traumakine being used to fund Bex , but now we have some action there , maybe it will be the case . But either way - he has options - be that Nordic Institutions , or Govt bodies .
They don't dillute for no good reason , and this certainly isn't a lifestyle share for the BOD .

Personally , I'll hold these shares for as long as I can , if I don't need the cash .

Lots of great questions - shame we can't understand the answers ....

00:13 Welcome to Markku's first challenge with inderesTV, can you tell us a little about yourself first?
01:00 How does drug development twist an iron wire?
02:25 Faro's drug development by twisting the iron wire: what, where and at what stage the development is.
(Bexmarilimab, Traumakine, Haematokine)
04:20 In light of the current research findings, what is Faro's perception of bexmarilimab (Clevegen) TAM, or total addressable Market?
06:25 How does he see the Bexmarilimab licensing situation, how far it is worth going alone and at what point would the inclusion of a deep pocket partner speed up market entry?
08:10 Partner diagnostics is becoming more common in the industry
09:15 There may be a trend in cancer treatments that there are more combination treatments, are more studies on different treatment combinations expected?
10:35 According to the latest release (25.8), the first patient has received Traumaquina in connection with HIBISCU phase 2/3. Can you illuminate the schedule more? On what schedule the remaining doses will be given and when the data may be available for publication
11:50 Is it the case that there are no originator antibodies to the Clever-1 receptor that are being developed other than by Faron? What prevents biosimilars from developing?
13:40 Is it good for the common good when in one's hands?
15:05 Cash situation: how long will the EUR 7 million cash register last in the light of current information? What solutions are being sought?
16:35 Dynamics of financing in a pharmaceutical company

Heres the interview .
Be interested on Finnish viewers opinions .

https://www.youtube.com/watch?v=WZDEgVtdOxw

Yes sat there looking at 80p thinking ' should sell now '
But greed thought - nahh hang in there .
Anyway , still above water just , and so much to come , so might as well stick in for the big gains now , a lot less hassle than jumping in and out , and end up missing out just for a few extra quid .

Not wanting to steal the catchphrase from a notorious past enigma , but the LSE presentation showed us that Markku is about to be the man of the moment in Finland .
No more ' we think ' , or ' we hope '

His words - be patient , we will get there . Not long now .

He has the science , and the data . Almost too much to handle as Bex comes of age , so Traumakine finally gets to shine too .

Manufacturing is gearing up to match their expected timelines .

We really are in the last phases before the metamorphasis from junior biotech to tier one player .

Guessing this is an ODX related bit of news coming rather than an overall LFT thing , as NCYT AVCT and ABDX all still down today .
Its like you have to bet on every horse in the race to guarantee a winner !

Indeed .First rule of AIM , every bottom has another bottom .
So glad to see upward movement here , hope everyone enjoys the upward journey as much as we did the first time .

Tell me about it , my whole portfolio is AIM .
I used to bite my nails over 20% price swings . Now its gotta be 50% before my coffee gets spurted out .
One day I'm going to get out of Dodge , but I've made some good money here over the years .
Just gotta try and play them at their own game lol

any clues as to whats causing this ?
As holders we know the price was way too low , but is there some incoming news thats made them stop the silly games .

Is my computer playing up , or am I actually experiencing a mining share going up ?

Can't see any detail on the programme for the events yet , but the LBA ( late breaking abstracts) will get published on the ESMO website as they get closer to the event .

Interesting again what this means about LBAs :

Their blurb below - basically you can only get a LBA , if back on the original deadline for submission on 14th May you didn't have the data you needed , and you haven't and won't publish it until ESMO .

So the data they have submitted is fresh stuff that they didn't have at the time , and obviously important enough to warrant a global audience .
This points in my opinion to stuff relating to frequency dosing and soluble clever-1 , as since may we have got the latest cohort data on solid tumours .

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 14 May 2021 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ESMO 2021, and a pre-planned analysis must be scheduled between the regular submission deadline of 14 May 2021 and the late-breaking submission deadline of 17 August 2021.

Sorry for posting like a madman this week , but I'm on a Faron high at the moment - after months of little or nothing , I'm just getting a bit excited .

Anyway - looking at ESMO Congress .

Late braking abstracts - which is what Faron have submitted - entry had to be in by 17th August .

The data in that abstract is then under embargo - ie can not be published anywhere until the congress .

Markku was chuffed that he got their findings into ESMO - but looks like whatever he submitted - we'll have to wait a few weeks to see .

Their wording :
Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above.

Data and information beyond what is included in all accepted abstracts, for example full data sets, may only be made public at the start of the official programme session during which the study is presented.

That new patent published is another banger .

It's the patent that covers use of Bex as a combination drug with PD1/PDL1 CPI's

What is the biggest PD1/PDL1 drug ? Keytruda - Mercks biggest selling drug at $14.4 billion sales a year .

So many bits of the jigsaw coming together , yet we are totally off the radar still ??